Although strict glycemic control has beneficial effects on microvascular complications (retinopathy, nephropathy or neuropathy), it does not seem to reduce the risk of cardiovascular disease, and it is associated with an increased risk of hypoglycemia in patients with DM2.3,6 Until recently, the antihyperglycemic drugs available have improved glycemic control, but without much benefits on cardiovascular and/or renal risk
For example, weight loss may lead to less pressure on the joints, better sleep, and improved mobility, all of which are important factors in fibromyalgia care
Most patients starting semaglutide injection begin at 0.25 mg once weekly, then move to 0.5 mg, 1 mg, 1.7 mg, and potentially 2.4 mg depending on tolerance and results
tirzepatide has been suggested to be cost-effective compared with s.c